DPYD
FDA Label Update for Xeloda®
In October 2025, the Food and Drug Administration revised its warning label for the common chemotherapy drug, capecitabine (Xeloda®).
The warning label now explicitly recommends that providers conduct pharmacogenomic testing (PGx) before beginning treatment. Why? Because certain DPYD genetic variants may cause some patients to experience critical or fatal side effects from the medication.
Aranscia® has multiple solutions at-the-ready that equip providers with diagnostics, clinical decision support, and software technologies that assist with compliance and assurance initiatives:
AccessDx PGx Profile already includes expanded DPYD variants – and we’re actively working with oncologists to support adoption of DPYD testing with fast-turnaround times and integrated ordering workflows.
Aranscia’s clinical pharmacists and PGxperts™ immediately validated this explicit guidance update and incorporated the revised warning information into the YouScript® knowledgebase.
Aranscia’s Software platforms Spesana and 2bPrecise®, plus YouScript clinical decision support solutions, deliver both pre- and post-test guidance for DPYD within existing provider-centric workflows.